<div id="readability-page-1"><p>Sagespring Wealth Partners LLC grew its position in  AstraZeneca PLC (NASDAQ:AZN - Free Report) by 21.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,094 shares of the company's stock after acquiring an additional 3,010 shares during the period. Sagespring Wealth Partners LLC's holdings in AstraZeneca were worth $1,195,000 at the end of the most recent quarter.</p><ul><li>How Does D-Wave Stack Up Against Quantum Competitors?</li></ul><p>A number of other hedge funds and other institutional investors also recently modified their holdings of AZN. Lindbrook Capital LLC raised its position in shares of  AstraZeneca by 1.9% in the 1st quarter. Lindbrook Capital LLC now owns 7,574 shares of the company's stock valued at $557,000 after buying an additional 141 shares in the last quarter.  Principal Securities Inc. raised its position in shares of  AstraZeneca by 0.5% in the 1st quarter. Principal Securities Inc. now owns 28,053 shares of the company's stock valued at $2,062,000 after buying an additional 142 shares in the last quarter.  Sage Mountain Advisors LLC raised its position in shares of  AstraZeneca by 3.4% in the 1st quarter. Sage Mountain Advisors LLC now owns 4,478 shares of the company's stock valued at $329,000 after buying an additional 147 shares in the last quarter.  Richardson Financial Services Inc. raised its position in shares of  AstraZeneca by 59.8% in the 2nd quarter. Richardson Financial Services Inc. now owns 398 shares of the company's stock valued at $28,000 after buying an additional 149 shares in the last quarter.  Finally, Evergreen Capital Management LLC raised its position in shares of  AstraZeneca by 0.7% in the 1st quarter. Evergreen Capital Management LLC now owns 23,709 shares of the company's stock valued at $1,743,000 after buying an additional 155 shares in the last quarter. Institutional investors own  20.35% of the company's stock. </p><h2>AstraZeneca Price Performance</h2><p>AZN stock opened at $84.83 on Thursday. The company has a 50 day simple moving average of $79.82 and a 200 day simple moving average of $73.69. The stock has a market cap of $263.09 billion, a price-to-earnings ratio of 31.89, a P/E/G ratio of 1.56 and a beta of 0.36. AstraZeneca PLC has a 1 year low of $61.24 and a 1 year high of $86.57. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.86 and a quick ratio of 0.67. </p><ul><li>Tempus AI Stock: Time to Double Down or Cut and Run?</li></ul><p>AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its earnings results on Tuesday, July 29th. The company reported $1.09 earnings per share for the quarter, hitting analysts' consensus estimates of $1.09. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The firm had revenue of $14.46 billion for the quarter, compared to analyst estimates of $14.08 billion. During the same period in the previous year, the firm posted $1.24 EPS. The company's revenue for the quarter was up 16.1% compared to the same quarter last year.  Research analysts anticipate that  AstraZeneca PLC will post 4.51 EPS for the current fiscal year. </p><h2>AstraZeneca Cuts Dividend</h2><p>The firm also recently announced a semi-annual dividend, which was paid on Monday, September 8th. Shareholders of record on Friday, August 8th were issued a dividend of $0.505 per share. This represents a yield of 200.0%. The ex-dividend date of this dividend was Friday, August 8th. AstraZeneca's payout ratio is presently 37.97%. </p><h2>Analyst Ratings Changes</h2><ul><li>Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal</li></ul><p>Several equities analysts have recently commented on the stock. Berenberg Bank  set a $97.00 target price on shares of AstraZeneca in a research report on Wednesday, July 9th. Weiss Ratings  reiterated a &#34;buy (b)&#34; rating on shares of AstraZeneca in a research report on Wednesday, October 8th. Four investment analysts have rated the stock with a Buy rating and one  has given a Hold rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $86.00.</p><p><b>Check Out Our Latest Stock Report on AstraZeneca</b></p><h2>AstraZeneca Company Profile</h2> (Free Report)<p>AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than AstraZeneca</li><li>When to Sell a Stock for Profit or Loss</li><li>Palantir’s New Healthcare Deal Boosts AI and Data Reach </li><li>Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time</li><li>GM's Billion-Dollar Bruise: GM's Strategic Pivot Makes It a Buy</li><li>The How And Why of Investing in Oil Stocks</li><li>Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead</li></ul><p><strong>Want to see what other hedge funds are holding AZN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVpO?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVpO"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in AstraZeneca Right Now?</h2><p>Before you consider AstraZeneca, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.</p><p>While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Sagespring Wealth Partners LLC increased its stake in AstraZeneca PLC by 21.4% in Q2, acquiring an additional 3,010 shares, bringing its total to 17,094 shares valued at $1,195,000. Other institutional investors also raised their positions in AstraZeneca. The stock opened at $84.83, with a market cap of $263.09 billion and a P/E ratio of 31.89. AstraZeneca reported Q2 earnings of $1.09 per share, meeting estimates, with revenue of $14.46 billion, up 16.1% year-over-year. The company recently announced a semi-annual dividend of $0.505 per share.</p>

Sagespring Wealth Partners LLC Purchases 3,010 Shares of AstraZeneca PLC $AZN